02:50:55 Europe / Stockholm


2024-02-14 15:48:00

Redeye comments on Ultimovacs’ Q4 2023 report, with the company having confirmed its intention to communicate INITIUM top-line data in March 2024e. These top-line data have been a long time coming and will represent a proverbial ‘fork in the road’ for Ultimovacs.

Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/